CoChat

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index; none of the 40 sources its claims cite is checked for support yet.

Abstract

Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer. Myeloid Cell Leukemia 1 (MCL1), a pro-survival member of the Bcl-2 protein family is associated with chemo-resistance in CRC. The ability of MCL1 to inhibit apoptosis by binding to the BH3 domains of pro-apoptotic Bcl-2 family members is a well-studied means by which this protein confers resistance to multiple anti-cancer therapies. We found that specific DNA damaging chemotherapies promote nuclear MCL1 translocation in CRC models. In p53 null CRC, this process is associated with resistance to chemotherapeutic agents, the mechanism of which is distinct from the classical mitochondrial protection. We previously reported that MCL1 has a noncanonical chemoresistance capability, which requires a novel loop domain that is distinct from the BH3-binding domain associated with anti-apoptotic function. Herein we disclose that upon treatment with specific DNA-damaging chemotherapy, this loop domain binds directly to alpha-enolase which in turn binds to calmodulin; we further show these protein−protein interactions are critical in MCL1’s nuclear import and chemoresistance. We additionally observed that in chemotherapy-treated p53 −/− CRC models, MCL1 nuclear translocation confers sensitivity to Bcl-xL inhibitors, which has significant translational relevance given the co-expression of these proteins in CRC patient samples. Together these findings indicate that chemotherapy-induced MCL1 translocation represents a novel resistance mechanism in CRC, while also exposing an inherent and targetable Bcl-xL co-dependency in these cancers. The combination of chemotherapy and Bcl-xL inhibitors may thus represent a rational means of treating p53 −/− CRC via exploitation of this unique MCL1-based chemoresistance mechanism.

Overview

CoChat Summary

TL;DR

DNA-damaging chemotherapy promotes MCL1 nuclear translocation in colorectal carcinoma through an ENO1/calmodulin-dependent, loop-domain-dependent mechanism, and this nuclear MCL1 drives chemoresistance in p53-deficient models. Nuclear MCL1 also creates sensitivity to Bcl-xL inhibition, suggesting a rational combination strategy.

Key findings

  • Doxorubicin (100 ng/ml) and oxaliplatin (10 μM) induced MCL1 nuclear translocation in CRC cell lines and in vivo; in p53−/− HCT116 and p53-deficient models this correlated with resistance to chemotherapy-induced senescence markers (β-gal, γH2AX, PML foci). SW480 and Colo205 were also resistant, though statistically insignificant compared with p53WT HCT116.
  • MCL1 nuclear translocation required the loop domain: deletion ∆198–207 impaired nuclear translocation and reduced chemoresistance, whereas BH3-domain deletion ∆208–350 did not. CaM inhibitors Ophiobolin A (5 µM) or calmidazolium chloride (5 µM) blocked translocation and increased PML/γH2AX foci.
  • ENO1 bridged MCL1 and CaM: ENO1 deficiency blocked doxorubicin-induced MCL1 nuclear translocation and sensitized p53−/− HCT116 to doxorubicin-induced DNA damage; MCL1/CaM co-immunoprecipitation failed in ENO1-deficient cells, and only full-length MCL1 co-immunoprecipitated with CaM and ENO1.
  • In human CRC IHC, primary CRC had medium/high Bcl-xL in 36/67 (54%), medium/high MCL1 in 19/67 (28%), intra-nuclear MCL1 in 1/67 (1%), and both mitochondrial/intra-nuclear MCL1 in 3/67 (4%); liver metastases had medium/high Bcl-xL in 33/56 (60%), medium/high MCL1 in 26/56 (46%), intra-nuclear MCL1 in 1/56 (2%), and both in 6/56 (11%). Bcl-2 was low/negative in 65/67 (97%) primary and 55/56 (98%) liver metastases. Nuclear MCL1 sensitized cells to Bcl-xL inhibitor A-1331852; in vivo only doxorubicin + A-1331852 inhibited HCT116 p53−/− tumor growth and lengthened survival, while ENO1-deficient tumors were inhibited by doxorubicin but not A-1331852.

Methods

  • In vitro: human CRC lines HCT116 p53+/+ and p53−/−, HT29, Colo205, SW480, and PDX cells; CRISPR MCL1/ENO1 derivatives; transfected Flag-MCL1 WT/mutants; treated with doxorubicin (100 ng/ml), oxaliplatin (10 μM), A-1331852 (1 μM), A-1210477 (10 μM), Ophiobolin A (5 µM), or calmidazolium chloride (5 μM).
  • In vivo: AOM/DSS inflammatory CRC mouse model; NSG xenografts with HCT116 p53−/− control or CRISPR ENO1 cells; PDX models; treatments included doxorubicin (1.2 mg/kg i.p. q3d) and/or A-1331852 (25 mg/kg PO q1d); xenograft experiments used 5 mice per group and 40 mice total without randomization.
  • Human samples and analysis: primary CRC and metastatic liver FFPE samples, described as a panel of n = 133 biopsies, stained by IHC for MCL1, Bcl-xL, and Bcl-2; scoring was negative/low vs medium/high; chi-square tests and odds ratios were used, alongside t-tests, immunoblotting, subcellular fractionation, immunofluorescence, co-immunoprecipitation, GST pulldown, viability assays, and senescence-associated β-galactosidase assays.

Limitations

  • The paper does not state limitations explicitly.
  • Evident from the text: in vivo xenograft experiments used 5 mice per group and 40 mice total without randomization, limiting statistical power and causal inference.
  • Evident from the text: some cell-line comparisons were statistically insignificant (SW480 and Colo205 resistance to chemotherapy-induced senescence compared with p53WT HCT116), and the human IHC findings are correlative co-expression data rather than direct proof of mechanism in patients.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41419-021-04334-y

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 MCL1 protein nuclear translocation can be induced by chemotherapy treatment. A Western blot for MCL1 protein level in CRC cell lines HCT116 wild type (WT), HCT116 p53−/−, Colo205, SW480, and HT29. Actin was used as loading controls. Data are representative of three independent experiments. B Representation of confocal microscopy images of CRC cell lines: HCT116 WT, HCT116 p53−/− Colo205, SW480, and HT29 treated with doxorubicin (100 ng/ml) (middle panel) and oxaliplatin (10 μM) and no drug treatment control (top panel). Cells were stained with anti-Tom20 (Green) and anti-MCL1 (Red) antibodies. Nucleus were stained with DAPI (Blue). C Mitochondria extraction and nuclear extraction were isolated from HCT116 p53−/− cells treated with doxorubicin (100 ng/ml) (left panel) or oxaliplatin (10 μM) (right panel). No drug treatment was used as control. Western blot was used to detect the protein level of MCL1. Tom 20 was used as an indicator of mitochondria and Histone H3 was used as an indicator of the nucleus. Data are representative of two independent experiments. Quantitative analysis of chemotherapy-induced senescence (CIS) in CRC cell lines and analyzed for β-gal activities (D), γH2AX nuclear bodies formation (E), and PML nuclear bodies formation (F). T-test is used to calculate the p-value, *, p < 0.05 and **, p < 0.01 for the indicated doxorubicin or oxaliplatin treated cell line compared with HCT116 p53−/− cells. Error bars represent +/−S.D.
Fig. 1 MCL1 protein nuclear translocation can be induced by chemotherapy treatment. A Western blot for MCL1 protein level in CRC cell lines HCT116 wild type (WT), HCT116 p53−/−, Colo205, SW480, and HT29. Actin was used as loading controls. Data are representative of three independent experiments. B Representation of confocal microscopy images of CRC cell lines: HCT116 WT, HCT116 p53−/− Colo205, SW480, and HT29 treated with doxorubicin (100 ng/ml) (middle panel) and oxaliplatin (10 μM) and no drug treatment control (top panel). Cells were stained with anti-Tom20 (Green) and anti-MCL1 (Red) antibodies. Nucleus were stained with DAPI (Blue). C Mitochondria extraction and nuclear extraction were isolated from HCT116 p53−/− cells treated with doxorubicin (100 ng/ml) (left panel) or oxaliplatin (10 μM) (right panel). No drug treatment was used as control. Western blot was used to detect the protein level of MCL1. Tom 20 was used as an indicator of mitochondria and Histone H3 was used as an indicator of the nucleus. Data are representative of two independent experiments. Quantitative analysis of chemotherapy-induced senescence (CIS) in CRC cell lines and analyzed for β-gal activities (D), γH2AX nuclear bodies formation (E), and PML nuclear bodies formation (F). T-test is used to calculate the p-value, *, p < 0.05 and **, p < 0.01 for the indicated doxorubicin or oxaliplatin treated cell line compared with HCT116 p53−/− cells. Error bars represent +/−S.D.CC BY · PubMed Central
Fig. 2 Chemotherapy treatment induces MCL1 protein nuclear translocation in Inflammatory CRC mouse model and PDX. A Mitochondria extraction and nuclear extraction were isolated from CRC mouse model treated with doxorubicin 1.2 mg/kg. No drug treatment was used as control. Western blot was used to detect the protein level of MCL1. Tom 20 was used as an indicator of mitochondria and Histone H3 was used as an indicator of the nucleus. Data are representative of two independent experiments. B Representation of microscopy images of inflammatory CRC mouse model. Tissues were stained with MCL1, PML, and γH2AX nuclear bodies. Yellow arrows show the nucleus located MCL1 proteins. C Quantitative analysis of chemotherapy-induced senescence (CIS) in CRC mouse model and analyzed for PML and γH2AX nuclear bodies. *p < 0.05 for the indicated doxorubicin treated tumor compared with no drug treatment controls. Error bars represent +/−S.D. D Representation of immunofluorescence microscopy images of p53KO tumors with or without doxorubicin treatment. Tissues were stained with MCL1, PML, and γH2AX nuclear bodies. E Quantitative analysis of CIS in p53KO model for PML and γH2AX nuclear bodies. T-test was performed to calculate p values, *, p < 0.05. F Representation of microscopy images of PDX model with wild type and p53 negative. The tissue was stained with anti-p53 antibodies. G Representation of microscopy images of PDX models. After injected with CRC cells, mice received 1.2 mg/kg doxorubicin every 3 days or were left untreated. Tissues were stained with MCL1, PML, and γH2AX nuclear bodies. The staining of MCL1 protein in single cells was shown in an enlarged picture on the top of the right side within each represented data. H, I Quantitative analysis of CIS in PDX model and analyzed for, PML and γH2AX nuclear bodies. Error bar represent +/−S.D. T-test was used to calculate the p values, *, p < 0.05 for the indicated doxorubicin treated PDX with and without wild type p53.
Fig. 2 Chemotherapy treatment induces MCL1 protein nuclear translocation in Inflammatory CRC mouse model and PDX. A Mitochondria extraction and nuclear extraction were isolated from CRC mouse model treated with doxorubicin 1.2 mg/kg. No drug treatment was used as control. Western blot was used to detect the protein level of MCL1. Tom 20 was used as an indicator of mitochondria and Histone H3 was used as an indicator of the nucleus. Data are representative of two independent experiments. B Representation of microscopy images of inflammatory CRC mouse model. Tissues were stained with MCL1, PML, and γH2AX nuclear bodies. Yellow arrows show the nucleus located MCL1 proteins. C Quantitative analysis of chemotherapy-induced senescence (CIS) in CRC mouse model and analyzed for PML and γH2AX nuclear bodies. *p < 0.05 for the indicated doxorubicin treated tumor compared with no drug treatment controls. Error bars represent +/−S.D. D Representation of immunofluorescence microscopy images of p53KO tumors with or without doxorubicin treatment. Tissues were stained with MCL1, PML, and γH2AX nuclear bodies. E Quantitative analysis of CIS in p53KO model for PML and γH2AX nuclear bodies. T-test was performed to calculate p values, *, p < 0.05. F Representation of microscopy images of PDX model with wild type and p53 negative. The tissue was stained with anti-p53 antibodies. G Representation of microscopy images of PDX models. After injected with CRC cells, mice received 1.2 mg/kg doxorubicin every 3 days or were left untreated. Tissues were stained with MCL1, PML, and γH2AX nuclear bodies. The staining of MCL1 protein in single cells was shown in an enlarged picture on the top of the right side within each represented data. H, I Quantitative analysis of CIS in PDX model and analyzed for, PML and γH2AX nuclear bodies. Error bar represent +/−S.D. T-test was used to calculate the p values, *, p < 0.05 for the indicated doxorubicin treated PDX with and without wild type p53.CC BY · PubMed Central
Fig. 3 The loop domain of MCL1 affects its nuclear translocation of MCL1 is affected by its loop domain and calmodulin. A Representation of confocal microscopy images of HCT116 p53−/− with CRISPR MCL1 cells. Cells were transiently transfected with empty vector, wild type MCL1, mutant MCL1 with ten amino acids deletion within the loop domain, and MCL1 mutant with C-terminal deletion. Doxorubicin (100 ng/ml) (lower panel) treatment was used to induce MCL1 nuclear translocation and no drug treatment was used as control (top panel). Cells were stained with anti-Tom20 (Green) and anti-MCL1 (Red) antibodies. Nucleus was stained with DAPI (Blue). B Western blot for wild type and mutant MCL1 protein level in HCT116 p53−/− with CRISPR MCL1. Actin was used as loading controls. Data are representative of two independent experiments. Quantitative analysis of chemotherapy-induced senescence (CIS) in CRISPR MCL1 HCT116 p53−/− cells with expression of wild type and mutant MCL1 and analyzed for γH2AX nuclear bodies formation (C), PML nuclear bodies formation (D). T-test was used to calculate the p values. *, p < 0.05 for the indicated MCL1 expression cells treated with doxorubicin compared with vector control cells. Error bars represent +/−S.D. E HCT116 p53−/− cells were treated with the CaM inhibitor ophiobolin A (Oph, 5 µM) or Calmidazolium chloride (CDZ 5uM) for two hours followed by treatment with 100 nM doxorubicin for 24 h. Cells were then fixed and stained for MCL1 (red) and Tom20 (green). No drug treatments were used as control. F. Co-immunopreciptation assay using anti-Flag antibody to pulldown CaM in MCL1 knockout HCT116 p53−/− cells with transient transfected with Flag-tagged MCL1 or empty vector. Input is 10% of the material used for immunoprecipitation. G, H Quantitative analysis of chemotherapy-induced senescence (CIS) in HCT116 p53−/− cells treated with doxorubicin and/or CaM inhibitor Oph (G) or CDZ (H) and analyzed for PML nuclear bodies formation (Gi and Hi) or γH2AX nuclear bodies formation (Gii and Hii). T-test was used to calculate the p values. *, p < 0.05 for the indicated HCT116 p53−/− cells treated with drugs compared with vector control cells. Error bars represent +/−S.D.
Fig. 3 The loop domain of MCL1 affects its nuclear translocation of MCL1 is affected by its loop domain and calmodulin. A Representation of confocal microscopy images of HCT116 p53−/− with CRISPR MCL1 cells. Cells were transiently transfected with empty vector, wild type MCL1, mutant MCL1 with ten amino acids deletion within the loop domain, and MCL1 mutant with C-terminal deletion. Doxorubicin (100 ng/ml) (lower panel) treatment was used to induce MCL1 nuclear translocation and no drug treatment was used as control (top panel). Cells were stained with anti-Tom20 (Green) and anti-MCL1 (Red) antibodies. Nucleus was stained with DAPI (Blue). B Western blot for wild type and mutant MCL1 protein level in HCT116 p53−/− with CRISPR MCL1. Actin was used as loading controls. Data are representative of two independent experiments. Quantitative analysis of chemotherapy-induced senescence (CIS) in CRISPR MCL1 HCT116 p53−/− cells with expression of wild type and mutant MCL1 and analyzed for γH2AX nuclear bodies formation (C), PML nuclear bodies formation (D). T-test was used to calculate the p values. *, p < 0.05 for the indicated MCL1 expression cells treated with doxorubicin compared with vector control cells. Error bars represent +/−S.D. E HCT116 p53−/− cells were treated with the CaM inhibitor ophiobolin A (Oph, 5 µM) or Calmidazolium chloride (CDZ 5uM) for two hours followed by treatment with 100 nM doxorubicin for 24 h. Cells were then fixed and stained for MCL1 (red) and Tom20 (green). No drug treatments were used as control. F. Co-immunopreciptation assay using anti-Flag antibody to pulldown CaM in MCL1 knockout HCT116 p53−/− cells with transient transfected with Flag-tagged MCL1 or empty vector. Input is 10% of the material used for immunoprecipitation. G, H Quantitative analysis of chemotherapy-induced senescence (CIS) in HCT116 p53−/− cells treated with doxorubicin and/or CaM inhibitor Oph (G) or CDZ (H) and analyzed for PML nuclear bodies formation (Gi and Hi) or γH2AX nuclear bodies formation (Gii and Hii). T-test was used to calculate the p values. *, p < 0.05 for the indicated HCT116 p53−/− cells treated with drugs compared with vector control cells. Error bars represent +/−S.D.CC BY · PubMed Central
Fig. 4 ENO1 interacts with MCL1 and promote its nuclear translocation under CIS condition. A Co-immunopreciptation assay using anti-Flag antibody to confirm ENO1 interact with MCL1 under CIS condition in MCL1 CRISPR HCT116 p53−/− cells with transient transfected with Flag-tagged MCL1. Input is 10% of the material used for immunoprecipitation. B Migration of GST tagged ENO1 protein is detect by Coomassie Blue staining. C GST pulldown assay using GST tagged ENO1 as bait to precipitate MCL1 protein, GST empty vector was used as control. D Western blot for ENO1 protein level in HCT116 p53−/− with CRISPR ENO1 and control cells. Actin was used as loading controls. Data are representative of two independent experiments. E. Mitochondria extraction and nuclear extraction were isolated from HCT116 p53−/− CRISPR ENO1 cells treated with doxorubicin (100 ng/ml). No drug treatment was used as control. Western blot was used to detect MCL1 protein level. Tom 20 was used as an indicator of mitochondria and Histone H3 was used as an indicator of the nucleus. Data are representative of two independent experiments. Quantitative analysis of chemotherapy-induced senescence (CIS) in HCT116 p53−/− with CRISPR ENO1 and control cells and analyzed for γH2AX nuclear bodies formation (F) or PML nuclear bodies formation (G). T-test is used to calculate the p-value. *, p < 0.05 for the indicated doxorubicin treated cells compared with no drug treatment controls. Error bars represent +/−S.D. H Co-immunopreciptation assay using anti-MCL1 antibody to pull down CaM (Cam) (top panel) and ENO1 (Middle panel) in HCT116 p53−/− with CRISPR ENO1 cells. Input is 10% of the material used for immunoprecipitation. I Co-immunopreciptation assay using anti-MCL1 antibody to pull down the CaM (Top panel) and ENO1 (Middle panel) in MCL1 CRISPR HCT116 p53−/− cells with transient transfected with wild type or mutant MCL1. Input is 10% of the material used for immunoprecipitation.
Fig. 4 ENO1 interacts with MCL1 and promote its nuclear translocation under CIS condition. A Co-immunopreciptation assay using anti-Flag antibody to confirm ENO1 interact with MCL1 under CIS condition in MCL1 CRISPR HCT116 p53−/− cells with transient transfected with Flag-tagged MCL1. Input is 10% of the material used for immunoprecipitation. B Migration of GST tagged ENO1 protein is detect by Coomassie Blue staining. C GST pulldown assay using GST tagged ENO1 as bait to precipitate MCL1 protein, GST empty vector was used as control. D Western blot for ENO1 protein level in HCT116 p53−/− with CRISPR ENO1 and control cells. Actin was used as loading controls. Data are representative of two independent experiments. E. Mitochondria extraction and nuclear extraction were isolated from HCT116 p53−/− CRISPR ENO1 cells treated with doxorubicin (100 ng/ml). No drug treatment was used as control. Western blot was used to detect MCL1 protein level. Tom 20 was used as an indicator of mitochondria and Histone H3 was used as an indicator of the nucleus. Data are representative of two independent experiments. Quantitative analysis of chemotherapy-induced senescence (CIS) in HCT116 p53−/− with CRISPR ENO1 and control cells and analyzed for γH2AX nuclear bodies formation (F) or PML nuclear bodies formation (G). T-test is used to calculate the p-value. *, p < 0.05 for the indicated doxorubicin treated cells compared with no drug treatment controls. Error bars represent +/−S.D. H Co-immunopreciptation assay using anti-MCL1 antibody to pull down CaM (Cam) (top panel) and ENO1 (Middle panel) in HCT116 p53−/− with CRISPR ENO1 cells. Input is 10% of the material used for immunoprecipitation. I Co-immunopreciptation assay using anti-MCL1 antibody to pull down the CaM (Top panel) and ENO1 (Middle panel) in MCL1 CRISPR HCT116 p53−/− cells with transient transfected with wild type or mutant MCL1. Input is 10% of the material used for immunoprecipitation.CC BY · PubMed Central
Fig. 5 Co-localization of overexpression MCL1 with Bcl-xL in clinical CRC samples. A Representation of protein expression for primary CRC and liver metastasis tissues. Rows represent individual patients. Primary CRC includes stages 1, 2, 3, and 4. Colon adenomas and adjacent tissues were used as control tissues. Expression patterns (negative, low, medium, and high) are shown for Bcl-2, Bcl-xL, and MCL1. Intra-nuclear MCL1 expression is marked with a single asterisk. Both nuclear and cytoplasmic expressions are marked with two asterisks. Two by two tables represent Bcl-xL vs MCL1 co-overexpression. Staining was categorized as follows: negative/low or medium/high by generating a composite score based on intensity (weak, moderate, and strong) and % positive tumor cells (<30%, 30–70%, >70%). Nuclear and/or cytoplasmic MCL1 and cytoplasmic Bcl-xL and Bcl-2 staining were considered positive. Chi-square tests were used to correlate marker expression with tumor location, stage, and grade. B Bar plot representing percentages of Bcl-xL/MCL1 Med/High co-expression, 95% CI (0.32–0.71, p < 0.05) in only CRC samples. C On the left: Forest plot representing OR for Bcl-2 Med/High and Bcl-xL Med/High between stage I/II and III/IV. On the right: Forest plot representing OR for Bcl-2 Neg/Low and MCL1 Neg/Low between Stage I−IV and IV Liver Mets. The graph is presented in a log scale. D Representative of primary CRC and mCRC tissues stained for various genes using 3,3’-Diaminobenzidine (DAB) Chromogen (Dako). The intensity of brown color is proportional to increased gene expression and graded: negative, low, medium, and high. Adenomas and normal adjacent tissues were used as positive and negative controls, respectively. Percentages represent only medium/high MCL1, Bcl-xL, and Bcl-2 expression within the sample.
Fig. 5 Co-localization of overexpression MCL1 with Bcl-xL in clinical CRC samples. A Representation of protein expression for primary CRC and liver metastasis tissues. Rows represent individual patients. Primary CRC includes stages 1, 2, 3, and 4. Colon adenomas and adjacent tissues were used as control tissues. Expression patterns (negative, low, medium, and high) are shown for Bcl-2, Bcl-xL, and MCL1. Intra-nuclear MCL1 expression is marked with a single asterisk. Both nuclear and cytoplasmic expressions are marked with two asterisks. Two by two tables represent Bcl-xL vs MCL1 co-overexpression. Staining was categorized as follows: negative/low or medium/high by generating a composite score based on intensity (weak, moderate, and strong) and % positive tumor cells (<30%, 30–70%, >70%). Nuclear and/or cytoplasmic MCL1 and cytoplasmic Bcl-xL and Bcl-2 staining were considered positive. Chi-square tests were used to correlate marker expression with tumor location, stage, and grade. B Bar plot representing percentages of Bcl-xL/MCL1 Med/High co-expression, 95% CI (0.32–0.71, p < 0.05) in only CRC samples. C On the left: Forest plot representing OR for Bcl-2 Med/High and Bcl-xL Med/High between stage I/II and III/IV. On the right: Forest plot representing OR for Bcl-2 Neg/Low and MCL1 Neg/Low between Stage I−IV and IV Liver Mets. The graph is presented in a log scale. D Representative of primary CRC and mCRC tissues stained for various genes using 3,3’-Diaminobenzidine (DAB) Chromogen (Dako). The intensity of brown color is proportional to increased gene expression and graded: negative, low, medium, and high. Adenomas and normal adjacent tissues were used as positive and negative controls, respectively. Percentages represent only medium/high MCL1, Bcl-xL, and Bcl-2 expression within the sample.CC BY · PubMed Central
Fig. 6 Nuclear translocation of MCL1 proteins affect its apoptosis activity in vitro and in vivo. A. Quantitative analysis of cell viability test in HCT116 p53−/− with CRISPR MCL1 cells treated with doxorubicin (100 ng/ml), Bcl-xL inhibitor A-1331852 (1uM), MCL1 inhibitor A-1210477 (10uM), or combined treatments for the indicated HCT116 p53−/− with CRISPR MCL1 cells expressing wild type or mutant MCL1. The solid line indicates the comparison of cells expressing full length or mutant MCL1 treated with Bcl-xL inhibitor A-1331852 with doxorubicin. The dotted line indicates the comparison of cells expressing mutant MCL1 treated with Bcl-xL inhibitor A-1331852 with doxorubicin or MCL1 inhibitor. T-test is used to calculate the p-value. *, p < 0.05. Error bars represent +/−S.D. B Quantitative analysis of cleaved caspase 3 staining in HCT116 p53−/− with CRISPR MCL1 cells expressing WT or mutant MCL1. Cells were treated with doxorubicin, Bcl-xL inhibitor A-1331852, MCL1 inhibitor A-1210477, or combined treatments. T-test is used to calculate the p-value, *, p < 0.05. Error bars represent +/−S.D. The solid line and dotted line are explained above. C tumor growth curves of HCT116 p53−/− xenografts. Mice (N = 5 for each group) were injected with HCT116 p53−/− cells. Mice received either doxorubicin (1.2 mg/kg i.p. q3d) or A-1331852 (25 mg/kg PO via oral gavage q1d), no drug treatment group were used as control. Error bars represent +/−S.D. T-test is used to calculate the p-value. *, p < 0.05 for tumor growth in the double treatment group, comparing with no drug treatment control group. N.S. indicate no significance according to p-value. D. mice (N = 5 for each group) survival data, with injected with doxorubicin and/or A-1331852 as indicated above. T-test is used to calculate the p value and *, p < 0.05 for the indicated doxorubicin and double treatment treated tumors (black solid line) comparing with no drug treatment controls (black dash line). N.S. indicate no significance according to p-value. Mice death is calculated as either mice that died during treatment or when tumor size reached 15 mm in diameter. E Tumor growth curves of xenograft HCT116 p53−/− cells with CRISPR ENO1. Mice (N = 5 for each group) were injected with HCT116 p53−/− cells with CRISPR ENO1. Mice received either doxorubicin and/or A-1331852 as indicated above. No drug treatment group was used as control. Error bars represent +/−S.D. T-test is used to calculate the p-value. *, p < 0.05 for tumor growth in doxorubicin and double treatment group, comparing with no drug treatment control group. N.S. indicate no significance according to p-value. F Quantitative analysis of chemotherapy-induced senescence (CIS) by staining γH2AX nuclear bodies for xenograft tumor tissue sections from (A and B). T-test is used to calculate the p-value. *, p < 0.05 for the indicated doxorubicin and double treatment treated tumors comparing with no drug treatment controls. Error bars represent +/−S.D. G Quantitative analysis of cell death by staining with cleaved caspase 3 for xenograft tumor tissue sections from (C and D). T-test is used to calculate the p-value. *, p < 0.05 for the indicated doxorubicin and double treatment treated tumors comparing with no drug treatment controls. Error bars represent +/−S.D.
Fig. 6 Nuclear translocation of MCL1 proteins affect its apoptosis activity in vitro and in vivo. A. Quantitative analysis of cell viability test in HCT116 p53−/− with CRISPR MCL1 cells treated with doxorubicin (100 ng/ml), Bcl-xL inhibitor A-1331852 (1uM), MCL1 inhibitor A-1210477 (10uM), or combined treatments for the indicated HCT116 p53−/− with CRISPR MCL1 cells expressing wild type or mutant MCL1. The solid line indicates the comparison of cells expressing full length or mutant MCL1 treated with Bcl-xL inhibitor A-1331852 with doxorubicin. The dotted line indicates the comparison of cells expressing mutant MCL1 treated with Bcl-xL inhibitor A-1331852 with doxorubicin or MCL1 inhibitor. T-test is used to calculate the p-value. *, p < 0.05. Error bars represent +/−S.D. B Quantitative analysis of cleaved caspase 3 staining in HCT116 p53−/− with CRISPR MCL1 cells expressing WT or mutant MCL1. Cells were treated with doxorubicin, Bcl-xL inhibitor A-1331852, MCL1 inhibitor A-1210477, or combined treatments. T-test is used to calculate the p-value, *, p < 0.05. Error bars represent +/−S.D. The solid line and dotted line are explained above. C tumor growth curves of HCT116 p53−/− xenografts. Mice (N = 5 for each group) were injected with HCT116 p53−/− cells. Mice received either doxorubicin (1.2 mg/kg i.p. q3d) or A-1331852 (25 mg/kg PO via oral gavage q1d), no drug treatment group were used as control. Error bars represent +/−S.D. T-test is used to calculate the p-value. *, p < 0.05 for tumor growth in the double treatment group, comparing with no drug treatment control group. N.S. indicate no significance according to p-value. D. mice (N = 5 for each group) survival data, with injected with doxorubicin and/or A-1331852 as indicated above. T-test is used to calculate the p value and *, p < 0.05 for the indicated doxorubicin and double treatment treated tumors (black solid line) comparing with no drug treatment controls (black dash line). N.S. indicate no significance according to p-value. Mice death is calculated as either mice that died during treatment or when tumor size reached 15 mm in diameter. E Tumor growth curves of xenograft HCT116 p53−/− cells with CRISPR ENO1. Mice (N = 5 for each group) were injected with HCT116 p53−/− cells with CRISPR ENO1. Mice received either doxorubicin and/or A-1331852 as indicated above. No drug treatment group was used as control. Error bars represent +/−S.D. T-test is used to calculate the p-value. *, p < 0.05 for tumor growth in doxorubicin and double treatment group, comparing with no drug treatment control group. N.S. indicate no significance according to p-value. F Quantitative analysis of chemotherapy-induced senescence (CIS) by staining γH2AX nuclear bodies for xenograft tumor tissue sections from (A and B). T-test is used to calculate the p-value. *, p < 0.05 for the indicated doxorubicin and double treatment treated tumors comparing with no drug treatment controls. Error bars represent +/−S.D. G Quantitative analysis of cell death by staining with cleaved caspase 3 for xenograft tumor tissue sections from (C and D). T-test is used to calculate the p-value. *, p < 0.05 for the indicated doxorubicin and double treatment treated tumors comparing with no drug treatment controls. Error bars represent +/−S.D.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 21 Not checked · 92 Own results and interpretations

61 more claims

Create a free account to see all 113 claims and to verify the 40 references still open.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

2 of 2

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14:575–83. · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J., Patil, D., DeVecchio, J., Kalady, M., Souers, A. J., Phillips, D. C., Li, X., & Gastman, B.
Affiliations
  • Cleveland Clinic (US)
  • Cleveland State University (US)
  • Case Western Reserve University (US)
  • AbbVie (United States) (US)
Corresponding author
  • Phoon, Yee Peng
  • Gastman, Brian
Venue
Cell Death & Disease
Published
2022-01-18
Volume
13
Issue
1
Pages
63-63
ISSN
2041-4889 (ISSN-L)
OpenAlex
W4206594822
Cited by
29
References
53
Citations by year
2026: 10 · 2025: 6 · 2024: 7 · 2023: 6
FWCI
1.31
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Abbvie Company This work was supported in part by NIH RO1 grant
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
Mcl-1, nuclear translocation, chemoresistance, colorectal cancer, Bcl-xL inhibitors, alpha-enolase, calmodulin, DNA-damaging chemotherapy, Bcl-2 family proteins, apoptosis, protein-protein interaction
MeSH terms
Humans, Colorectal Neoplasms, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma. https://app.cochat.ai/papers/10.1038/s41419-021-04334-y
The paper
Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J., Patil, D., DeVecchio, J., Kalady, M., Souers, A. J., Phillips, D. C., Li, X., & Gastman, B. (2022). MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma. Cell Death & Disease. https://doi.org/10.1038/s41419-021-04334-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.